ixekizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	5083	1143503-69-8

Description:

Molecule	Description
Synonyms: ixekizumab (genetical recombination) ixekizumab LY2439821 taltz	A humanized anti-interleukin 17 monoclonal antibody used for the treatment of PSORIASIS. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

ixekizumab (genetical recombination)
ixekizumab
LY2439821
taltz

A humanized anti-interleukin 17 monoclonal antibody used for the treatment of PSORIASIS.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
2.90	mg	P

ADMET properties:

None

Approvals:

Show entries

Search:

Date	Agency	Company
Feb. 25, 2016	EMA
July 4, 2016	PMDA	Eli Lilly Japan
March 22, 2016	FDA	ELI LILLY AND CO

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Therapy interrupted	989.84	23.42	337	12944	32118	63443623
Injection site erythema	623.90	23.42	317	12964	82857	63392884
Injection site pain	565.58	23.42	346	12935	129454	63346287
Injection site swelling	548.70	23.42	244	13037	47328	63428413
Injection site reaction	503.40	23.42	245	13036	58279	63417462
COVID-19	353.20	23.42	245	13036	112858	63362883
Therapy cessation	327.81	23.42	149	13132	30308	63445433
Psoriasis	231.25	23.42	171	13110	86786	63388955
Drug ineffective	207.68	23.42	578	12703	1044187	62431554
Injection site urticaria	190.67	23.42	81	13200	13992	63461749

Showing 1 to 10 of 59 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Injection site pain	485.00	28.44	214	7501	38791	34910425
Therapy interrupted	382.03	28.44	135	7580	13562	34935654
Injection site reaction	361.72	28.44	128	7587	12905	34936311
Injection site erythema	347.77	28.44	131	7584	15768	34933448
Psoriasis	272.14	28.44	144	7571	38668	34910548
Injection site swelling	266.63	28.44	99	7616	11428	34937788
Therapy cessation	209.97	28.44	93	7622	16880	34932336
Drug ineffective	172.99	28.44	336	7379	456415	34492801
Device defective	151.90	28.44	35	7680	731	34948485
COVID-19	123.73	28.44	116	7599	77434	34871782

Showing 1 to 10 of 56 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Therapy interrupted	1470.50	24.24	439	14390	30902	79698657
Injection site erythema	477.54	24.24	250	14579	77947	79651612
COVID-19	467.39	24.24	316	14513	157358	79572201
Injection site pain	457.44	24.24	290	14539	129548	79600011
Injection site swelling	454.46	24.24	206	14623	46926	79682633
Therapy cessation	432.52	24.24	186	14643	37376	79692183
Injection site reaction	391.95	24.24	195	14634	54590	79674969
Psoriasis	235.36	24.24	167	14662	89420	79640139
Illness	228.74	24.24	129	14700	46382	79683177
Ear infection	223.94	24.24	115	14714	34317	79695242

Showing 1 to 10 of 75 entries

Previous1 2 3 4 5…8Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L04AC13	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors
FDA EPC	N0000191495	Interleukin-17A Antagonist
FDA MoA	N0000191494	Interleukin-17A Antagonists
MeSH PA	D003879	Dermatologic Agents

Showing 1 to 4 of 4 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Ankylosing spondylitis	indication	9631008	DOID:7147
Psoriatic arthritis	indication	156370009	DOID:9008
Plaque psoriasis	indication	200965009
Pustular psoriasis	indication	200973000
Erythrodermic psoriasis	indication	200977004
Non-radiographic axial spondyloarthritis	indication	713777005

Showing 1 to 6 of 6 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interleukin-17A	Cytokine	Q16552	IL17_HUMAN	ANTIBODY BINDING				DRUG LABEL	DRUG LABEL

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
016752	NDDF
1745099	RXNORM
31578	MMSL
4035606	VANDF
724037000	SNOMEDCT_US
7541	IUPHAR_LIGAND_ID
763603002	SNOMEDCT_US
9467	INN_ID
BTY153760O	UNII
C3489764	UMLSCUI

Showing 1 to 10 of 15 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
TALTZ	HUMAN PRESCRIPTION DRUG LABEL	1	0002-1445	INJECTION, SOLUTION	80 mg	SUBCUTANEOUS	BLA	30 sections
TALTZ	HUMAN PRESCRIPTION DRUG LABEL	1	0002-1445	INJECTION, SOLUTION	80 mg	SUBCUTANEOUS	BLA	30 sections
TALTZ	HUMAN PRESCRIPTION DRUG LABEL	1	0002-1445	INJECTION, SOLUTION	80 mg	SUBCUTANEOUS	BLA	30 sections
TALTZ	HUMAN PRESCRIPTION DRUG LABEL	1	0002-7724	INJECTION, SOLUTION	80 mg	SUBCUTANEOUS	BLA	30 sections
TALTZ	HUMAN PRESCRIPTION DRUG LABEL	1	0002-7724	INJECTION, SOLUTION	80 mg	SUBCUTANEOUS	BLA	30 sections
TALTZ	HUMAN PRESCRIPTION DRUG LABEL	1	0002-7724	INJECTION, SOLUTION	80 mg	SUBCUTANEOUS	BLA	30 sections

Showing 1 to 6 of 6 entries

Previous1Next